A cleavable peptide adapter augments the activity of targeted toxins in combination with the glycosidic endosomal escape enhancer SO1861
Treatment with tumor-targeted toxins attempts to overcome the disadvantages of conventional cancer therapies by directing a drug ’s cytotoxic effect specifically towards cancer cells. However, success with targ...
Source: BMC Biotechnology - Category: Biotechnology Authors: Finn J. Schulze, Mazdak Asadian-Birjand, Michael Pradela, Nicole Niesler, Gregor Nagel and Hendrik Fuchs Tags: Research Source Type: research